EUVIMEDEUVIMED entdecken
Crossref

Expression of LHFPL2 in hepatocellular carcinoma and its association with prognosis after transarterial chemoembolization

Lei Sun, Kang Chen, Xiao-Li Zhu

World Journal of Gastrointestinal Surgery · 27.06.2026 · 18 (6)

DOI: 10.4240/wjgs.116682 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastrointestinal Surgery, online erschienen am 27.06.2026. Verfasst von Lei Sun und 2 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Transarterial chemoembolization (TACE) is a standard treatment for recurrent hepatocellular carcinoma (HCC) after liver resection. However, resistance to TACE considerably limits its efficacy and worsens patient prognosis. Identifying molecular markers that predict TACE response is crucial for individualized treatment strategies. AIM To investigate lipoma HMGIC fusion partner-like 2 (LHFPL2) expression in patients with HCC and its association with TACE efficacy and overall survival (OS). METHODS A retrospective study was conducted including 60 patients with HCC who underwent ≥ 3 standardized TACE treatments for recurrence after curative hepatectomy between January 2014 and December 2020 at Jiangsu Provincial People’s Hospital and Wuxi People’s Hospital. The patients were divided into TACE-resistant (n = 30) and non-resistant (n = 30) groups. LHFPL2 protein expression in tumor tissues was assessed using immunohistochemistry, and its association with clinicopathological features, TACE response, and OS was analyzed. The Kaplan-Meier method, log-rank test, and Cox regression models were used to evaluate prognostic value. RESULTS The TACE-resistant group exhibited significantly higher LHFPL2 expression than the non-resistant group (P < 0.05). Significant differences were observed between the two groups in hepatitis B virus carrier status, alpha-fetoprotein (AFP) levels, tumor differentiation, and LHFPL2 expression (P < 0.05). The median OS in the LHFPL2 high-expression group was 2.28 years, which was significantly shorter than that in the low expression group (P < 0.05). Multivariate Cox regression analysis indicated that high LHFPL2 expression, AFP ≥ 400 ng/mL, and TACE resistance were independent risk factors for OS (P < 0.05). A combined prognostic model using LHFPL2 and AFP revealed that patients with high LHFPL2 and AFP ≥ 400 ng/mL had the poorest prognosis (median OS 1.44 years), whereas patients with low LHFPL2 and AFP < 400 ng/mL had the best prognosis (median OS not reached), with significant differences (P < 0.05). CONCLUSION High LHFPL2 expression was closely associated with TACE resistance and was an independent predictor of poor prognosis in patients with HCC. Combining LHFPL2 with AFP enhanced prognostic stratification, providing a novel molecular marker and clinical basis for personalized therapy and TACE response prediction.

Zitieren

APA

Sun, L., Chen, K., & Zhu, X. (2026). Expression of LHFPL2 in hepatocellular carcinoma and its association with prognosis after transarterial chemoembolization. World Journal of Gastrointestinal Surgery, 18(6). https://doi.org/10.4240/wjgs.116682

Vancouver

Sun L, Chen K, Zhu X. Expression of LHFPL2 in hepatocellular carcinoma and its association with prognosis after transarterial chemoembolization. World Journal of Gastrointestinal Surgery. 2026;18(6). doi:10.4240/wjgs.116682

BibTeX
@article{Sun2026,
  author = {Sun, Lei and Chen, Kang and Zhu, Xiao-Li},
  title = {Expression of LHFPL2 in hepatocellular carcinoma and its association with prognosis after transarterial chemoembolization},
  journal = {World Journal of Gastrointestinal Surgery},
  year = {2026},
  volume = {18},
  number = {6},
  doi = {10.4240/wjgs.116682}
}
Kostenlos starten →